Back to Search Start Over

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial

Authors :
David H. Adams
John L. Berk
Fabio Barroso
Shiangtung W. Jung
M D Benson
Peter D. Gorevic
Isabel Conceição
Fabrizio Salvi
A. K. Wang
Peter J. Dyck
Brian M. Drachman
Arnt V. Kristen
Giuseppe Vita
V. Plante-Bordeneuve
Acary Souza Bulle Oliveira
Stephen B. Heitner
Edward Gane
Laura Obici
Spencer D. Guthrie
Michael L. Pollock
Josep Maria Campistol Plana
Hartmut Schmidt
M. Waddington Cruz
Morton Scheinberg
T. Coelho
Jesse Kwoh
Giampaolo Merlini
Josep Gamez
Thomas H. Brannagan
Michael Polydefkis
Morie A. Gertz
S.G. Hughes
Carol J. Whelan
Source :
Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, European Journal of Neurology
Publication Year :
2020
Publisher :
Wiley-Blackwell, 2020.

Abstract

Background and purpose: Hereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition throughout the body, including the peripheral nerves. The efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of TTR protein production, were demonstrated in the pivotal NEURO-TTR study in patients with hATTR polyneuropathy. Here, the long-term efficacy and safety of inotersen are assessed in an ongoing open-label extension (OLE) study. Methods: Patients who completed NEURO-TTR were eligible to enroll in the OLE (NCT02175004). Efficacy assessments included the modified Neuropathy Impairment Score plus seven neurophysiological tests composite score (mNIS + 7), the Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN) questionnaire total score and the Short-Form 36 Health Survey (SF-36) Physical Component Summary (PCS) score. Safety and tolerability were also assessed. Results: Overall, 97% (135/139) of patients who completed NEURO-TTR enrolled in the OLE. Patients who received inotersen for 39 cumulative months in NEURO-TTR and the OLE continued to show benefit; patients who switched from placebo to inotersen in the OLE demonstrated improvement or stabilization of neurological disease progression by mNIS + 7, Norfolk QOL-DN and SF-36 PCS. No new safety concerns were identified. There was no evidence of increased risk for grade 4 thrombocytopenia or severe renal events with increased duration of inotersen exposure. Conclusion: Inotersen slowed disease progression and reduced deterioration of quality of life in patients with hATTR polyneuropathy. Early treatment with inotersen resulted in greater long-term disease stabilization than delayed initiation. Routine platelet and renal safety monitoring were effective; no new safety signals were observed. info:eu-repo/semantics/publishedVersion

Details

Language :
English
Database :
OpenAIRE
Journal :
Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, European Journal of Neurology
Accession number :
edsair.doi.dedup.....2fec3a4d6f680baab6454dc5284b33bf